EcoR1 Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

EcoR1 Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-332,522	Closed	-$18M	–	57
2024 Q4	$18M	Buy	+332,522	New	+$17M	0.68%	28
2022 Q2	–	Sell	-200,000	Closed	-$2.22M	–	87
2022 Q1	$2.22M	Hold	200,000	–	–	0.07%	63
2021 Q4	$1.98M	Hold	200,000	–	–	0.06%	56
2021 Q3	$1.99M	Hold	200,000	–	–	0.07%	52
2021 Q2	$2.07M	Hold	200,000	–	–	0.08%	54
2021 Q1	$2.04M	Hold	200,000	–	–	0.09%	52
2020 Q4	$2.27M	Buy	+200,000	New	+$2.12M	0.12%	50

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

EcoR1 Capital's MLTX Position: Q1 2025 in Review

EcoR1 Capital sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2025, closing a stake of 332,522 shares — an estimated $18M sold.

EcoR1 Capital first reported a position in MLTX in Q4 2020 and held it in 7 quarters. The position peaked at $18M in Q4 2024. 136 funds tracked by Wall St. Rank hold MLTX as of Q1 2025.

EcoR1 Capital reported no remaining MoonLake Immunotherapeutics position as of Q1 2025 after selling out during the quarter.
EcoR1 Capital sold 332,522 MoonLake Immunotherapeutics shares in Q1 2025, an estimated $18M.
EcoR1 Capital first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 7 quarters.
EcoR1 Capital's MoonLake Immunotherapeutics position peaked at $18M in Q4 2024.
136 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2025.

Based on EcoR1 Capital's 13F filing for Q1 2025, filed 15 May 2025.